参考文献：磷脂绘制的PEI基微米形式适用身体内部siRNA*多药抗药*友链：//www.nature.com/articles/gt201497作家：埃塞克斯郡中南部G纳瓦罗P·萨巴钱达尼，多元性膜M Trivedi，S Movassaghian＆总监裁托尔奇林节选：实体线线瘤中P-糖核血清过表明介导的多药抗药力(MDR)是好几种肺癌晚期化疗药错误的首要各种因素。本设计评价了磷脂修饰语的分不高子量聚乙稀亚胺(DOPE-PEI)納米膜血清广泛用于静脉血管运送*P-糖核血清siRNA至*的郊果，之后制定目标是调节甲状腺炎癌的MDR。先是，我都设计了DOPE-PEI納米膜血清的生态学分布图制作及及PEG涂膜在皮下组织甲状腺炎*实体线模型中的影响。注塑后四小时候，PEG化膜血清顺利通过强化的融入性和停留滞后效应，在实体线线瘤中沉淀了了8%的注塑的用药量(ID)，因为PEG介导的间歇时间间隔提高，在血清中沉淀了了22%的ID。前者，我都明确了DOPE-PEI/siRNA介导的P-gp调整合作阿霉素(Dox)肺癌晚期化疗药在MCF-7/MDR异种迁移瘤中的药效和稳定性。每月注塑siRNA納米药物和Dox，一直有5周，使*对那样有效的用药量的Dox制造比较敏理性，并使*表面积与参考组相对来说变大了两倍。种对Dox药效的减少归因于DOPE-PEI药物介导的肿瘤切除*中明显的队列特女性朋友P-gp调整。

Multidrug resistance (MDR) mediated by P-glycoprotein overexpression in solid tumors is a major factor in the failure of many forms of chemotherapy. Here we evaluated phospholipid-modified, low-molecular-weight polyethylenimine (DOPE-PEI) nanocarriers for intravenous delivery of anti-P-pg siRNA to tumors with the final goal of modulating MDR in breast cancer. First, we studied the biodistribution of DOPE-PEI nanocarriers and the effect of PEG coating in a subcutaneous breast tumor model. Four hours postinjection, PEGylated carriers showed an 8% injected dose (ID) accumulation in solid tumor via the enhanced permeability and retention effect and 22% ID in serum due to a prolonged, PEG-mediated circulation. Second, we established the therapeutic efficacy and safety of DOPE-PEI/siRNA-mediated P-gp downregulation in combination with doxorubicin (Dox) chemotherapy in MCF-7/MDR xenografts. Weekly injection of siRNA nanopreparations and Dox for up to 5 weeks sensitized the tumors to otherwise non-effective doses of Dox and decreased the tumor volume by threefold vs controls. This therapeutic improvement in response to Dox was attributed to the significant, sequence-specific P-gp downregulation in excised tumors mediated by the DOPE-PEI formulations.渭南pg电子娱乐游戏app 生物体给予相应好产品：DSPE-PyreneDSPE-ThiolDSPE-PEG-GE11(二硬脂酰基磷脂酰工业乙醇胺-聚乙二醇-*细胞核仁衣发展因素EGFR靶向治疗肽)DSPE-PEG-HisDSPE-PEG-cRGD(二硬脂酰基磷脂酰甲醇胺-聚乙二醇-聚合素靶点环肽)ALC-0315DOPE-PEG-MalDSPE-PEG-M2pepDSPE-PEG-cisplatinDSPEGPC3靶点肽-PEG-DSPE以内好的文章方面渠道各大杂志或文献资料，如不侵犯著作权请认识我删出！